- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00405548
Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.
June 3, 2015 updated by: Horng Chen, Mayo Clinic
To Define in Human Preclinical Diastolic Dysfunction (PDD) the Actions of Chronic Administration of Subcutaneous (SQ) BNP on the Left Ventricular, Renal and Humoral Function and on the Integrated Response to Acute Sodium Loading
The purpose of this research study is to evaluate the effects of cardiac hormone replacement with SQ (subcutaneous or under the skin) injection of BNP (brain natriuretic peptide, a hormone produced by the heart) on the pumping ability of the heart, kidney function and levels of different hormones in the blood in response to an intravenous salt solution.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Prior to initiation of the study, subjects will be stabilized for at least one week on a no added salt diet (120 milliequivalent (mEq) Na/Day) which will be maintained during the study.
Participants in this study will be randomized to receive BNP or placebo (an inactive, saline shot).
The participant will need to give themselves a shot in their stomach (similar to diabetics giving themselves insulin) twice a day for twelve weeks.
The study requires a screening visit to determine eligibility and discuss the study.
At this visit a blood draw for heart and liver function and a six minute walk will be done.
There will also be two other outpatient visits and two inpatient stays, for 48 hours, in the Clinical Research Unit at St. Marys Hospital.
During the two overnight stays, blood and urine samples will be done to get heart and kidney function as well as a research echocardiogram.
An acute saline load (0.9% normal saline 1.25 ml/kg/min for 1 hour) will be given and blood and urine samples collected After enrollment, the study lasts for twelve weeks.
It is planned to treat 2 subjects with active drug per each placebo subject to improved the precision of between group comparison.
Study Type
Interventional
Enrollment (Actual)
41
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects with ejection fraction of greater than 50% with moderate or severe diastolic dysfunction as assessed by Doppler echocardiography
- No signs or symptoms of congestive heart failure and who have not been hospitalized for heart failure
Exclusion criteria:
- Myocardial Infarction (MI) within 3 months of screening
- Unstable angina within 14 days of screening, or any evidence of myocardial ischemia
- Significant valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or biopsy proven active myocarditis
- Severe congenital heart diseases
- Sustained ventricular tachycardia or ventricular fibrillation within 14 days of screening
- Second or third degree heart block without a permanent cardiac pacemaker
- Stroke within 3 months of screening, or other evidence of significantly compromised central nervous system (CNS) perfusion
- Total bilirubin of > 1.5 mg/dL or other liver enzymes > 1.5 times the upper limit of normal (mg/dL = milligrams per deciliter)
- Serum creatinine of > 3.0 mg/dL
- Serum sodium of < 125 mEq/dL or > 160 mEq/dL (milliequivalents per deciliter)
- Serum potassium of < 3.5 mEq/dL or > 5.0/dL
- Serum digoxin level of > 2.0 ng/ml (nanograms per milliliter)
- Systolic pressure of < 85 mm Hg (millimeters of mercury)
- Hemoglobin < 10 gm/dl (grams per deciliter)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: BNP (nesiritide)
BNP 10 micrograms/Kg twice per day given subcutaneously for 12 weeks
|
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Saline solution given subcutaneously twice per day for 12 weeks (packaged to match active comparator)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Urinary Sodium Excretion in Response to Saline Load
Time Frame: Baseline, 12 weeks
|
Renal (or kidney) function was measured by the sodium or salt in the urine, following administration of a pre-specified amount of saline (salt).
|
Baseline, 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Urinary Flow in Response to Saline Load
Time Frame: Baseline, 12 weeks
|
Urinary flow is a measure of renal (or kidney) function and was measured in milliliters per minute.
|
Baseline, 12 weeks
|
Change in Glomerular Filtration Rate (GFR) in Response to Saline Load
Time Frame: Baseline, 12 weeks
|
Renal or kidney function was measured by GFR determined by iothalamate clearance.
GFR describes the flow rate of filtered fluid through the kidney measured in milliliters per minute per 1.73 m^2 of body surface area.
A lower GFR means the kidney is not filtering normally.
An estimated GFR of less than 60 mg/ml/1.73
m^2 of body surface area is considered to be impaired kidney function.
|
Baseline, 12 weeks
|
Left Ventricular (LV) Filling Pressure
Time Frame: Baseline, 12 weeks
|
LV diastolic function as measured by Doppler echocardiography.
E/e' is the ratio of the mitral inflow velocity (E) to the mitral annulus tissue Doppler velocity (e').
A decrease in the ratio indicates a lower filling pressure and improved LV diastolic function.
|
Baseline, 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2008
Primary Completion (ACTUAL)
April 1, 2011
Study Completion (ACTUAL)
August 1, 2012
Study Registration Dates
First Submitted
November 29, 2006
First Submitted That Met QC Criteria
November 29, 2006
First Posted (ESTIMATE)
November 30, 2006
Study Record Updates
Last Update Posted (ESTIMATE)
July 1, 2015
Last Update Submitted That Met QC Criteria
June 3, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05-004190
- P01HL076611 (U.S. NIH Grant/Contract)
- UL1RR024150 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Left Ventricular Diastolic Dysfunction
-
AdventHealthCompletedDiastolic Heart Failure | Left Ventricular Diastolic Dysfunction | Left Ventricular Diastolic CollapseUnited States
-
Montreal Heart InstituteCompletedLeft Ventricular Function Diastolic Dysfunction | Fluid ResponsivenessCanada
-
Icahn School of Medicine at Mount SinaiForest LaboratoriesCompletedHypertension | Left Ventricular Diastolic DysfunctionUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruiting
-
Universitätsklinikum Hamburg-EppendorfCompletedLeft Ventricular Diastolic DysfunctionGermany
-
IRCCS San RaffaeleCompletedLeft Ventricular Diastolic DysfunctionItaly
-
Daiichi Sankyo, Inc.CompletedHeart Failure, Congestive | Heart Decompensation | Left Ventricular Failure | Myocardiopathies | Systolic or Diastolic Left Ventricular DysfunctionUnited States, Canada
-
Severance HospitalCompletedKidney TransplantationKorea, Republic of
-
Newcastle-upon-Tyne Hospitals NHS TrustCompletedLeft Ventricular Function Systolic Dysfunction | Left Ventricular Function Diastolic Dysfunction | AgeingUnited Kingdom
-
Helena DOMINGUEZRigshospitalet, DenmarkActive, not recruitingAtrial Fibrillation | Left Ventricular Diastolic DysfunctionDenmark
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States